CD4 and neoplasm: Harnessing HLA-II–restricted TCRs from CD4+ T cells may promote systemic antitumor immunity and overcome defects in HLA-I expression in tumors, and on its own, CD4+ TCR-T has mediated tumor regression in humans (18).